NYSEAMERICAN:BTX - BioTime Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.35 +0.05 (+2.17 %)
(As of 06/24/2018 10:52 AM ET)
Previous Close$2.35
Today's Range$2.28 - $2.36
52-Week Range$2.08 - $3.21
Volume1.50 million shs
Average Volume438,988 shs
Market Capitalization$338.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
BioTime logoBioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%

Miscellaneous

EmployeesN/A
Outstanding Shares126,870,000

The Truth About Cryptocurrencies

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) announced its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. The biotechnology company earned $0.70 million during the quarter, compared to analyst estimates of $0.83 million. BioTime had a net margin of 828.55% and a return on equity of 30.68%. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

1 Wall Street analysts have issued 1 year target prices for BioTime's shares. Their predictions range from $8.00 to $8.00. On average, they anticipate BioTime's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest in May. As of May 31st, there was short interest totalling 9,427,853 shares, an increase of 3.7% from the May 15th total of 9,095,764 shares. Based on an average trading volume of 267,081 shares, the short-interest ratio is currently 35.3 days. Currently, 7.5% of the company's shares are short sold. View BioTime's Current Options Chain.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Dr. Michael D. West, Co-CEO & Director (Age 65)
  • Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Dan L. Lawrence, Director of Investor Relations & Corp. Communications
  • Dr. Stephana E. Patton Ph.D., J.D., Gen. Counsel and Corp. Sec. (Age 47)

Has BioTime been receiving favorable news coverage?

Media headlines about BTX stock have trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTime earned a media sentiment score of 0.08 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.63 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are BioTime's major shareholders?

BioTime's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.76%), DAFNA Capital Management LLC (0.14%), Schwab Charles Investment Management Inc. (0.14%) and Millennium Management LLC (0.09%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

Which major investors are selling BioTime stock?

BTX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC and Millennium Management LLC. View Insider Buying and Selling for BioTime.

Which major investors are buying BioTime stock?

BTX stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $2.35.

How big of a company is BioTime?

BioTime has a market capitalization of $338.75 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (BTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.